Dexrazoxane

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 800 publications

Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients.

Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients.

Journal: Journal of chemotherapy (Florence, Italy)

Published: March 13, 2026

Heart transplantation in pediatric oncology patients.

Heart transplantation in pediatric oncology patients.

Journal: JHLT open

Published: March 11, 2026

Emerging Cardioprotective Strategies Beyond Dexrazoxane: SGLT2 Inhibitors, Drug Repurposing, and Mitochondrial Approaches in Doxorubicin Cardiotoxicity.

Emerging Cardioprotective Strategies Beyond Dexrazoxane: SGLT2 Inhibitors, Drug Repurposing, and Mitochondrial Approaches in Doxorubicin Cardiotoxicity.

Journal: Journal of applied toxicology : JAT

Published: February 16, 2026

Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management.

Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management.

Journal: Frontiers in cardiovascular medicine

Published: February 15, 2026

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Journal: Trials

Published: February 13, 2026

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies.

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies.

Journal: Drug metabolism reviews

Published: February 10, 2026

Molecular insights into doxorubicin-induced cardiotoxicity and phytochemical-based cardioprotection: challenges and future strategies.

Molecular insights into doxorubicin-induced cardiotoxicity and phytochemical-based cardioprotection: challenges and future strategies.

Journal: Drug metabolism reviews

Published: February 10, 2026

Chemotherapy-induced oxidative injury in pediatric acute lymphoblastic leukemia: The role of N-acetylcysteine (Review).

Chemotherapy-induced oxidative injury in pediatric acute lymphoblastic leukemia: The role of N-acetylcysteine (Review).

Journal: Biomedical reports

Published: February 02, 2026

Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study.

Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study.

Journal: ESC heart failure

Published: January 10, 2026

Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research.

Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research.

Journal: Medicines (Basel, Switzerland)

Published: December 03, 2025

Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology.

Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology.

Journal: Discoveries (Craiova, Romania)

Published: November 29, 2025

Anthracyclines and the Heart: A Double-edged Sword With Therapeutic Hopes.

Anthracyclines and the Heart: A Double-edged Sword With Therapeutic Hopes.

Journal: Journal of the Saudi Heart Association

Published: November 15, 2025

Showing 1-12 of 800

Last Updated: 06/30/2026